The application of mucoadhesive polymers in nasal drug delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 323-336

  Jiang, Lingmin ^a   Gao, Lei ^a   Wang, Xiaoqing ^a   Tang, Liang ^a   Ma, Jianli ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Absorption enhancer; Microspheres; Mucoadhesion; Mucociliary clearance; Nanoparticles; Nasal drug delivery; Polymer

Indexed keywords

APOMORPHINE; CALCITONIN; CARBOMER; CARBOPOL 974P; CARBOXYMETHYLCELLULOSE; CELLULOSE DERIVATIVE; CHITOSAN; CIPROFLOXACIN; CYANOCOBALAMIN; DESMOPRESSIN; DOPAMINE; GENTAMICIN; GLUCAGON; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; KETOROLAC; KETOROLAC TROMETAMOL; LACTOSE; LEUPRORELIN; LEVODOPA; METHYLCELLULOSE; METOCLOPRAMIDE; MICROCRYSTALLINE CELLULOSE; MIDAZOLAM; POLYACRYLIC ACID; POLYCARBOPHIL; POLYMER; STARCH; UNINDEXED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRY POWDER; GEL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; SOLUTION AND SOLUBILITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77249166118     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903170750     Document Type: Article

References (130)

1. Ugwoke MI, Agu RU, Verbeke N, Kinget R. (2005). Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev, 57:1640-1665
2. Turker S, Onur E, Ozer Y. (2004). Nasal route and drug delivery systems. Pharm World Sci, 26:137-142
3. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. (2007). Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm, 337:1-24.
4. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Release, 87:187-198
5. Horvát S, Fehér A, Wolburg H, Sipos P, Veszelka S, Tóth A, et al. (2009). Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm, 72:252-259
6. Charlton ST, Davis SS, Illum L. (2007). Nasal administration of an angiotensin antagonist in the rat model: Effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int J Pharm, 338:94-103.
7. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH. (2008). Delivery of interferon-beta to the monkey nervous system following interanasal administration. Neuroscience, 152:785-797
8. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70:735-740
9. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11:1-18.
10. Kublik H, Vidgren MT. (1998). Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev, 29:157-177
11. Kang ML, Jiang H, Kang SG, Guo DD, Lee DY, Cho Ch, et al. (2007). Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine, 25:4602-4610
12. Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, et al. (2008). Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm, 363:139-148
13. Ugwoke MI, Verbeke N, Kinget R. (2001). The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol, 53:3-22.
14. Song K, Fasano A, Eddington ND. (2008). Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator. Eur J Pharm Biopharm, 69:231-237
15. Khafagy E, Morishita M, Isowa K, Imai J, Takayama K. (2009). Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release, 133:103-108
16. Li L, Nandi I, Kim KH. (2002). Development of an ethyl lauratebased microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm, 237:77-85.
17. Zaki NM, Awad GAS, Mortada ND, Abd ElHady SS. (2006). Rapid-onset intranasal delivery of metoclopramide hydrochloride: Part I: Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm, 327:89-96.
18. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. (2001). Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm, 222:109-119
19. Behl CR, Pimplaskar HK, Sileno AP, Xia WJ, Gries WJ, Demeireles JC, et al. (1998). Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev, 29:117-133
20. Farraj NF, Johansen BR, Davis SS, Illum L. (1990). Nasal administration of insulin using bioadhesive microspheres as a delivery system. J Control Release, 13:253-261
21. Hascicek C, Gonul N, Erk N. (2003). Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: Preparation and in vitro characterization. Farmaco, 58:11-16
22. Longer MA, Robinson JR. (1986). Fundamental aspects of bioadhesion. Pharm Int, 7:114-117
23. Gu JM, Robinson JR, Leung SH. (1988). Binding of acrylic polymers to mucin/epithelial surfaces: Structure-property relationships. Crit Rev Ther Drug Carrier Syst, 5:21-67.
24. Salamat-Miller N, Chittchang M, Johnston TP. (2005). The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev, 57:1666-1691
25. Jimenez-Castellanos MR, Zia H, Rhodes CT. (1993). Mucoadhesive drug delivery systems. Drug Dev Ind Pharm, 19:143-194
26. Sriamornsak P, Wattanakorn N, Nunthanid J, Puttipipatkhachorn S. (2008). Mucoadhesion of pectin as evidence by wettability and chain interpenetration. Carbohydr Polymers, 74:458-467
27. Smart JD. (2005). The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev, 57:1556-1568
28. Jabbari E, Wisniewski N, Peppas NA. (1993). Evidence of mucoadhesion by chain interpenetration at a poly (acrylic acid)/mucin interface using ATR-FTIR spectroscopy. J Control Release, 26:99-108.
29. Grabovac V, Guggi D, Bernkop-Schnürch A. (2005). Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev, 57:1713-1723
30. Accili D, Menghi G, Bonacucina G, Martino PD, Palmieri GF. (2004). Mucoadhesion dependence of pharmaceutical polymers on mucosa characteristics. Eur J Pharm Sci, 22:225-234
31. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Madhusudan Rao Y. (2008). Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm, 34:1246-1266
32. Ahuja A, Khar RK, Ali J. (1997). Mucoadhesive drug delivery systems. Drug Dev Ind Pharm, 23:489-515.
33. Schipper NGM, Hoogstraate JA, De Boer AG, Varum KM, Artursson P. (1997). Chitosans as absorption enhancers for poorly absorbable drugs. 2: Mechanism of absorption enhancement. Pharm Res, 14:923-929
34. Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15:1326-1331
35. Ugwoke MI, Agu RU, Vanbilloen H, Baetens J, Augustijns P, Verbeke N, et al. (2000). Scintigraphic evaluation in rabbits of nasal drug delivery systems based on Carbopol 971p ((R)) and carboxymethylcellulose. J Control Release, 68:207-214
36. Ishikawa F, Murano M, Hiraishi M, Yamaguchi T, Tamai I, Tsuji A. (2002). Insoluble powder formulation as an effective nasal drug delivery system. Pharm Res, 19:1097-1194
37. Quadir M, Zia H, Needham TE. (2000). Development and evaluation of nasal formulations of ketorolac. Drug Deliv, 7:223-229
38. Dondeti P, Zia H, Needham TE. (1995). In vivo evaluation of spray formulations of human insulin for nasal delivery. Int J Pharm, 122:91-105.
39. Garcia-Arieta A, Torrado-Santiago S, Goya L, Torrado JJ. (2001). Spray-dried powders as nasal absorption enhancers of cyanocobalamin. Biol Pharm Bull, 24:1411-1416
40. Teshima D, Yamauchi A, Makino K, Kataoka Y, Arita Y, Nawata H, et al. (2002). Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm, 233:61-66
41. Suzuki Y, Makino Y. (1999). Mucosal drug delivery using cellulose derivatives as a functional polymer. J Control Release, 62:101-107
42. Ikeda K, Murata K, Kobayashi M, Noda K. (1992). Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull, 40:2155-2158
43. Zaki NM, Awada GA, Mortadaa ND, Abd Elhadyb SS. (2007). Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci, 32:296-307.
44. Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, Sigurdsson HH, Sigfusson SD, Masson M, et al. (2001). Cyclodextrin solubilization of benzodiazepines: Formulation of midazolam nasal spray. Int J Pharm, 212:29-40.
45. Ozsoy Y, Tuncel T, Can A, Akev N, Birteksoz S, Gerceker A. (2000). In vivo studies on nasal preparations of ciprofloxacin hydrochloride. Pharmazie, 55:607-609
46. Vidgren P, Vidgren M, Arppe J, Hakuli T, Laine E, Paronen P. (1992). In vitro evaluation of spray-dried mucoadhesive microspheres for nasal administration. Drug Dev Ind Pharm, 18:581-597
47. Bommareddy GS, Paker-Leggs S, Saripella KK, Neau SH. (2006). Extruded and spheronized beads containing Carbopol 974P to deliver nonelectrolytes and salts of weakly basic drugs. Int J Pharm, 321:62-71.
48. Qi H, Chen W, Huang C, Li L, Chen C, Li W, et al. (2007). Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm, 337:178-187
49. Funke AP, Günther C, Müller RH, Lipp R. (2002). In-vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS. J Control Release, 82:63-70.
50. Liu W, Hu M, Liu W, Xue C, Xu H, Yang X. (2009). Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm, 364:135-141
51. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. (2006). Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm, 64:246-254
52. Ugwoke MI, Sam E, Van Den Mooter G, Verbeke N, Kinget R. (1999). Nasal mucoadhesive delivery systems of the anti- Parkinsonian drug, apomorphine: Influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm, 181:125-138
53. Ugwoke MI, Sam E, Van Den Mooter G, Verbeke N, Kinget R. (1999). Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci, 9:213-219
54. El-Shafy MA, Kellaway IW, Taylor G, Dickinson PA. (2000). Improved nasal bioavailability of FITC-Dextran (Mw 4300) from mucoadhesive microspheres in rabbits. J Drug Target, 7:355-361
55. Shahiwala A, Misra A. (2004). Nasal delivery of levonorgestrel for contraception: An experimental study in rats. Fertil Steril, 81:893-898
56. Callens C, Remon JP. (2000). Evaluation of starchmaltodextrin- Carbopol 974P mixtures for the nasal delivery of insulin in rabbits. J Control Release, 66:215-220
57. Preda M, Leucuta SE. (2003). Oxprenolol-loaded bioadhesive microspheres: Preparation and in vitro/in vivo characterization. J Microencapsul, 20:777-789
58. Ugwoke MI, Kaufmann G, Verbeke N, Kinget R. (2000). Intranasal bioavailability of apomorphine from carboxymethylcellulose- based drug delivery systems. Int J Pharm, 202:125-131
59. Callens C, Adriaens E, Dierckens K, Remon JP. (2001). Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J Control Release, 76:81-91.
60. Critchley H, Davis SS, Farraj NF, Illum L. (1994). Nasal absorption of desmopressin in rats and sheep, effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol, 46:651-656
61. Illum L, Farraj NF, Critchley H, Davis SS. (1988). Nasal administration of gentamicin using a novel microsphere delivery system. Int J Pharm, 46:261-265
62. Illum L, Farraj NF, Davis SS, Johansen BR, O'Hagan DT. (1990). Investigation of the nasal absorption of biosynthetic human growth hormone in sheep-use of a bioadhesive microsphere delivery system. Int J Pharm, 63:207-211
63. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. (1987). Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm, 39:189-199
64. Edman P, Bjork E, Ryden L. (1992). Microspheres as a nasal delivery system for peptides. J Control Release, 21:165-172
65. Björk E, Edman P. (1988). Degradable starch microspheres as a nasal delivery system for insulin. Int J Pharm, 47:233-238
66. Björk E, Edman P. (1990). Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm, 62:187-192
67. Mao S, Chen J, Wei Z, Liu H, Bi D. (2004). Intranasal administration of melatonin starch microspheres. Int J Pharm, 272:37-43.
68. Callens C, Pringels E, Remon JP. (2003). Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm, 250:415-422
69. Vivien N, Buri P, Balant L, Lacroix S. (1994). Nasal absorption of metoclopramide administered to man. Eur J Pharm Biopharm, 40:228-231
70. Jain AK, Khar RK, Ahmed FJ, Diwan PV. (2008). Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm, 69:426-435
71. Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, et al. (2002). Intranasal delivery of morphine. J Pharmacol Exp Ther, 301:391-400.
72. Pringels E, Vervaet C, Verbeeck R, Foreman P, Remon JP. (2008). The addition of calcium ions to starch/carbopol mixtures enhances the nasal bioavailability of insulin. Eur J Pharm Biopharm, 68:201-206
73. Pereswetoff-Morath L. (1998). Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev, 29:185-194
74. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178:55-65.
75. Björk E, Bjurstrom S, Edman P. (1991). Morphologic examination of rabbit nasal mucosa after nasal administration of degradable starch microspheres. Int J Pharm, 75:73-80.
76. Holmberg K, Bjork E, Bake B, Edman P. (1994). Influence of degradable starch microspheres on human nasal mucosa. Rhinology, 32:74-77
77. Issa MM, Koping-Hoggard M, Artursson P. (2005). Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov Today, 2:1-6.
78. Paul W, Garside CP. (2000). Chitosan, a drug carrier for the 21st century: A review. STP Pharm Sci, 10:5-22.
79. Illum L. (2002). Nasal drug delivery: New developments and strategies. Drug Discov Today, 7:1184-1189
80. Cui F, Qian F, Yin C. (2006). Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharm, 316:154-161
81. Soane RJ, Hinchcliffe M, Davis SS, Illum L. (2001). Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm, 217:183-191
82. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res, 11:1358-1361
83. Luessen HL, De-Leeuw BJ, Langemeyer M, De-Boer AG, Verhoef JC, Unginger HE. (1996). Mucoadhesive polymers in peroral peptide drug delivery. IV. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res, 13:1668-1672
84. Mei D, Mao S, Sun W, Wang Y, Kissel T. (2008). Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur J Pharm Biopharm, 70:874-881
85. Krauland AH, Guggi D, Bernkop-Schnurch A. (2006). Thiolated chitosan microparticles: A vehicle for nasal peptide drug delivery. Int J Pharm, 307:270-277 (Pubitemid 41820424)
86. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. (2008). Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm, 68:526-534
87. Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, et al. (2005). Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosanbased powder formulations. Eur J Pharm Sci, 26:9-15.
88. Varshosaz J, Sadrai H, Alinagari R. (2004). Nasal delivery of insulin using chitosan microspheres. J Microencapsul, 21:761-774
89. Sinswat P, Tengamnuay P. (2003). Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: Comparison with hydroxypropyl-beta and dimethyl-beta-cyclodextrins. Int J Pharm, 257:15-22.
90. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al. (2002). Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res, 19:998-1008.
91. Yu S, Zhao Y, Wu F, Zhang X, Lü W, Zhang H, et al. (2004). Nasal insulin delivery in the chitosan solution: In vitro and in vivo studies. Int J Pharm, 281:11-23.
92. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, et al. (2006). Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm, 307:9-15.
93. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. (2002). In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm, 231:73-82.
94. Sankar C, Rani M, Srivastava AK, Mishra B. (2001). Chitosan based pentazocine microspheres for intranasal systemic delivery: Development and biopharmaceutical evaluation. Pharmazie, 56:223-226
95. Lim ST, Forbes B, Martin GP, Brown MB. (2001). In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS Pharm- SciTech, 2(4):20.
96. Lim ST, Martin GP, Berry DJ, Brown MB. (2000). Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J Control Release, 66:281-292
97. Brime B, Ballesteros MP, Frutos P. (2000). Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration. J Microencapsul, 6:777-784
98. Wang J, Tabata Y, Morimoto K. (2006). Aminated gelatin microspheres as a nasal delivery system for peptide drugs: Evaluation of in vitro release and in vivo insulin absorption in rats. J Control Release, 113:31-37
99. Miyamoto M, Natsume H, Iwata S, Ohtake K, Yamaguchi M, Kobayashi D, et al. (2001). Improved nasal absorption of drugs using poly-L-arginine: Effects of concentration and molecular weight of poly-L-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats. Eur J Pharm Biopharm, 52:21-30.
100. Zaki NM, Mortada ND, Awad GAS, Abd Elhady SS. (2006). Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm, 327:97-103.
101. Kotzé AF, Lueßen HL, de Boer AG, Verhoef JC, Junginger HE. (1999). Chitosan for enhanced intestinal permeability: Prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci, 7:145-151
102. Thanou M, Verhoef JC, Verheijden JHM, Junginger HE. (2000). Intestinal absorption of octeriotide: N-Trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci, 89:951-957
103. Hamman JH, Stander M, Kotzé AF. (2002). Effect of the degree of quaternization of N-trimethyl chitosan chloride on absorption enhancement: In vivo evaluation in rat nasal epithelia. Int J Pharm, 232:235-242
104. Gavini E, Rassu G, Muzzarelli C, Cossu M, Giunchedi P. (2008). Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm, 68:245-252
105. Tengamnuay P, Sahamethapat A, Sailasuta A, Mitra AK. (2000). Chitosans as nasal absorption enhancers of peptides: Comparison between free amine chitosans and soluble salts. Int J Pharm, 197:53-67.
106. Aspden TJ, Illum L, Skaugrud Ø. (1996). Chitosan as a nasal delivery system: Evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur J Pharm Sci, 4:23-31.
107. Borchard G. (2001). Chitosans for gene delivery. Adv Drug Deliv Rev, 52:145-150
108. Lai WF, Lin MCM. (2009). Nucleic acid delivery with chitosan and its derivatives. J Control Release, 134:158-168
109. Jabbal-Gill I, Fisher AN, Farraj N, Pitt CG, Davis SS, Illum L. (1998). Intranasal absorption of granulocyte-colony stimulating factor (G-CSF) from powder formulations, in sheep. Eur J Pharm Sci, 6:1-10.
110. Jabbal-Gill I, Fisher AN, Rappuoli R. (1998). Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine, 16:2039-2046
111. Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, et al. (2005). Effective nasal influenza vaccine delivery using chitosan. Vaccine, 23:4367-4374
112. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. (2000). Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun, 68:5764-5770
113. Nakamura F, Ohta R, Machida Y, Nagai T. (1996). In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int J Pharm, 134:173-181
114. Ishikawa F, Katsura M, Tamai I, Tsuji A. (2001). Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int J Pharm, 224:105-114
115. Lee WA, Narog BA, Patapoff TW, Wang YJ. (1991). Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer-to-protein ratio. J Pharm Sci, 80:725-729
116. Garmise RJ, Staats HF, Hickey AJ. (2007). Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech, 8(4):E81.
117. Ascentiis AD, Bettini R, Caponetti G, Catellani PL, Peracchia MT, Santi P, et al. (1996). Delivery of nasal powders of betacyclodextrin by insufflation. Pharm Res, 13:734-738
118. Fransen N, Bjork E, Nystrom C. (2007). Development and characterisation of interactive mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery. Eur J Pharm Biopharm, 67:370-376
119. Tas C, Ozkan Y, Savaser A, Baykara T. (2004). In vitro and ex vivo permeation studies of chlorpheniramine maleate gels prepared by carbomer derivatives. Drug Dev Ind Pharm, 30:637-647
120. Ghosh PK, Umrethia ML, Murthy RS. (2006). Thermoreversiblemucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech, 7(3):67.
121. Wu J, Wei W, Wang LY, Su ZG, Ma GH. (2007). A thermosensitive hydrogel based on quaternized chitosan and poly (ethylene glycol) for nasal drug delivery system. Biomaterials, 28:2220-2232
122. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila- Jato JL, Alonso MJ. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 16:1576-1581
123. Van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. (2003). Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine, 21:1400-1408
124. Wang SM, Inthavong K, Wen J, Tu JY, Xue CL. (2009). Comparison of micron- sand nanoparticle deposition patterns in a realistic human nasal cavity. Respir Physiol Neurobiol, 166:142-151
125. Donovan MD, Huang Y. (1998). Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev, 29:147-155
126. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. (2006). Preparation and characterization of proteinloaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release, 111:107-116
127. Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. (2009). Chitosan/ cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm, 71:257-263
128. Csaba N, Garcia-Fuentes M, Alonso MJ. (2008). Nanoparticles for nasal vaccination. Adv Drug Deliv Rev, 61:140-157
129. Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. (2001). Chitosan for mucosal vaccination. Adv Drug Deliv Rev, 52:139-144
130. Van der Lubben IM, Verhoef JC, Van-Aelst A, Borchard G, Junginger HE. (2001). Chitosan microparticles for oral vaccination: Preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials, 22:687-694 (Pubitemid 32112293)